Drug Details

General Information of the Drug (ID: DR7247)
Name
Lopinavi
Disease Human immunodeficiency virus disease [ICD-11: 1C62] Phase 4 [1]
DrugBank ID
DB01601
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Miltefosine      Coconut leaflet phytoplasma     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model BALB/c mice were used in this study.
                    Experimental
                    Result(s)		 LPV- MFS combination therapy can be effective in the treatment of VL/HIV co-infected patients and provides data that can help to guide a possible therapeutic strategy in VL/HIV co-infection.
References
Reference 1 ClinicalTrials.gov (NCT00771498) An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
Reference 2 Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: In vitro and in vivo Approaches. Front Cell Infect Microbiol. 2019 Jun 28;9:229.
 Download Picture         KEGG Link